该研究结果于3月16日在线发表于《BMC Cancer》。 研究结果显示,EB病毒的EBNA1-IgA、VCA-IgA抗体单阳或双阳人群,发生肝癌的风险是双抗体全阴人群的两倍。校正了年龄和HBsAg后,EBNA1-IgA和VCA-IgA的检测值与原发性肝癌的比值比(ORs)分别为1.59和...
该研究结果于3月16日在线发表于《BMCCancer》。 研究结果显示,EB病毒的EBNA1-IgA、VCA-IgA抗体单阳或双阳人群,发生肝癌的风险是双抗体全阴人群的两倍。校正了年龄和HBsAg后,EBNA1-IgA和VCA-IgA的检测值与原发性肝癌的比值比(ORs)分别为1.59和1.60。HBsAg和EB病毒抗体阳性人群比两种标志物阴性人群患肝癌的风险增加...
34. Shin DY, Kim A, Kang HJ, Park S, Kim DW, Lee SS. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-...
It may also be linked to Hodgkin lymphoma and some cases of stomach cancer. EBV-related cancers are more common in Africa and parts of Southeast Asia. Overall, very few people who have been infected with EBV will ever develop these cancers. https://www.cancer.org/cancer/risk-prevention/...
(which will lyse with each reactivation, spilling new virions), and the more long term risk of autoimmune disorders or even possibly cancer. EBV lives latent (dormant) much of its life in the host, but “the virus can persist throughout life with low or intermittent levels of virion ...
The finding of high incidence of NPC only in select populations (Southern Chinese and other Asians, North Africans, and Eskimos) and persistence of high risk in migrants from these areas has suggested the importance of genetic factors in this cancer. Additional evidence implicating genetic factors ...
e6c第22卷第5期2000年l0月右江民族医学院学报JournalofYoujiangMedicalCollegeforNationalitiesVoI.22No5Oct.2000EBV感染与肺癌的关系卢运龙。赵德海(右江是族医学院学教研室。广西百色533000)关键词:;霉遮堑丑二垦堑童童醚垄董耋中圉分类号:R7302313文献标识码:A目前有研究认为呼吸道是EBV潜伏的最大场所,主要是通过...
美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)和中国临床肿瘤学会 (Chinese Society of Clinical Oncology,CSCO) 指南并未针对EBV+ DLBCL-NOS患者提供特殊的治疗方案,因此一线治疗仍参考DLBCL-NOS 的治疗方案,即采用含利妥昔单抗的免疫化疗方案[10]。既往CHOP方案(环磷酰胺+多柔比星+长春新碱+泼尼...
图5 治疗过程中 cfEBV DNA 在指导个性化治疗中的应用(图源:Cancer Cell) 该项研究有助于了解 cfEBV DNA 在癌症患者中的变化模式,并发现它与患者的生存率和治疗反应之间存在关联。这为使用 cfEBV DNA 作为实时动态风险监测的生物标志物提供了依据,并为个体化癌症患者管理提供了指导。此外,研究还揭示了 cfEBV DNA...
4 EBV+DLBCL-NOS的治疗现状及预后 目前,尚未有特定药物或方案获批用 于EBV+DLBCL-NOS患者的一线治疗.美国 国立综合癌症网络(National Comprehensive Cancer Network,NCCN)和中国临床肿瘤学会 (Chinese Society of Clinical Oncology,CSCO) 指南并未针对EBV+DLBCL-NOS患者提供特殊 的治疗方案,因此一线治疗仍参考DLBCL...